Larimar Therapeutics Inc.
LRMR | NASDAQ
$3.83
+$0.04 (+1.06%)
At close: Sep 21, 2026, 4:00 PM ET
$3.83
$0 (0.00%)
Pre-market:
Sep 22, 2026, 7:00 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | 155K |
Gross Profit | n/a | n/a | n/a | n/a | n/a | -155K |
Operating Income | -172.5M | -90.89M | -41.76M | -36.53M | -50.47M | -42.8M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -165.67M | -80.6M | -36.95M | -35.36M | -50.64M | -42.48M |
Net Income | -165.67M | -80.6M | -36.95M | -35.36M | -50.64M | -42.33M |
Selling & General & Admin | 18.27M | 17.61M | 14.09M | 12.28M | 12.07M | 11.4M |
Research & Development | 154.22M | 73.28M | 27.67M | 24.25M | 38.4M | 31.25M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 172.5M | 90.89M | 41.76M | 36.53M | 50.47M | 42.65M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 172.5M | 90.89M | 41.76M | 36.53M | 50.47M | 42.8M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 72.95M | 61.26M | 43.9M | 25.76M | 17.16M | 11.88M |
Shares Outstanding (Diluted) | 72.95M | 61.26M | 43.9M | 25.76M | 17.16M | 11.88M |
EPS (Basic) | -2.27 | -1.32 | -0.84 | -1.33 | -2.93 | -3.56 |
EPS (Diluted) | -2.27 | -1.32 | -0.84 | -1.33 | -2.93 | -3.56 |
EBITDA | -165.32M | -80.29M | -36.64M | -35.04M | -50.31M | -42.65M |
EBIT | -165.67M | -80.6M | -36.95M | -35.36M | -50.64M | -42.8M |
Depreciation & Amortization | 350K | 318K | 311K | 318K | 326K | 155K |
Add to Watchlist
Select watchlists to add or remove LRMR